/stocks — the workspaceLOADING
Pfizer sells the blood thinner Eliquis, Prevnar pneumococcal vaccines, and a cancer lineup expanded by its $43 billion Seagen acquisition. Revenue from its COVID products, Comirnaty and Paxlovid, has fallen sharply from pandemic peaks.
PFIZER INC (PFE) is a pharmaceutical preparations company. Piotroski F-Score 4/7. 25 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-04 from PFE's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Led by Albert Bourla · see pay & career →
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
A plain-English read on PFE plus an auto-SWOT — built from PFE's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PFE using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Brandes Investment Partners (Charles Brandes) | $255.7M | 1.8% of portfolio |
| Fairfax Financial (Prem Watsa) | $27.8M | 1.4% of portfolio |
Projected from PFE's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment PFE files its announcement.
PFE has rallied after 5 of its last 8 earnings reports.
Earnings reactions have been mild.
PFE has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+5.9% and -1.2%).
A more typical earnings reaction has been approximately ±0.9%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-05 | +0.9% |
| 2026-02-03 | +0.5% |
| 2025-11-04 | -0.2% |
| 2025-08-05 | +1.7% |
| 2025-04-29 | +5.9% |
| 2025-02-04 | +0.9% |
| 2024-10-29 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -1.2% |
| 2024-07-30 | -0.6% |
| Company | Stake value | % of company owned |
|---|---|---|
| ORIC PHARMACEUTICALS INCORIC | $57.7M | 4.6% |
| ALLOGENE THERAPEUTICS INCALLO | $49.8M | 6.4% |
| ARVINAS INCARVN | $34.9M | 5.4% |
| CELCUITY INCCELC | $31.3M | 0.61% |
| ZURA BIO LTDZURA | $16.8M | 3.0% |
| WAVE LIFE SCIENCES LTDWVE | $11.9M | 0.97% |
| PYXIS ONCOLOGY INCPYXS | $9.2M | 11.1% |
| CARIBOU BIOSCIENCES INCCRBU | $8.3M | 4.7% |
| SPERO THERAPEUTICS INCSPRO | $5.5M | 4.1% |
| BIOHAVEN LTDBHVN | $4.2M | 0.34% |
| CARDIFF ONCOLOGY INCCRDF | $3.7M | 3.5% |
| ZENTALIS PHARMACEUTICALS INCZNTL | $2.0M | 1.3% |
| NEXTCURE INCNXTC | $1.5M | 4.2% |
| AGOMAB THERAPEUTICS NVAGMB | $814K | 0.22% |
| Q32 BIO INCQTTB | $737K | 0.60% |
Long US equity positions from PFE's own 13F-HR (SEC), reported quarterly and lagged up to 45 days. “% of company owned” = reported shares ÷ that company's latest shares outstanding.
| DAMICO JENNIFER B.SVP & Controller | SELL | $51K | view → |